

**For Immediate Release**

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,  
Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com>

**Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with  
Calcium/Natural Vitamin D3/Magnesium**

**Tokyo, Japan (May 31, 2013)** – Daiichi Sankyo Company, Limited today announced the launch in Japan of Denotas® chewable combination tablets with calcium, natural vitamin D3, magnesium (precipitated calcium carbonate/cholecalciferol (vitamin D3)/magnesium carbonate combination tablets).

Nitto Pharmaceutical Industries, Ltd. received approval on February 28, 2013 for the manufacturing and marketing of Denotas® for the treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab).

**Product overview**

Launch date: May 31, 2013

Product name	DENOTAS CHEWABLE COMBINATION TABLETS
Agent	Calcium, natural vitamin D3, magnesium combination tablets
Drug price	20.90 yen per tablet Announced May 31, 2013
Indications and usage	Treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab)
Dosage and administration	Two tablets to be administered orally every day under normal circumstances. Dosage to be increased or decreased based on condition of the patient and clinical test results.
Approval date for manufacturing and marketing	February 28, 2013
Manufacturing and marketing	Nitto Pharmaceutical Industries, Ltd.
Marketing	Daiichi Sankyo Co., Ltd.